CN103380212B - 用于单细胞分选与增强ipsc重新编程的细胞培养平台 - Google Patents

用于单细胞分选与增强ipsc重新编程的细胞培养平台 Download PDF

Info

Publication number
CN103380212B
CN103380212B CN201180068009.0A CN201180068009A CN103380212B CN 103380212 B CN103380212 B CN 103380212B CN 201180068009 A CN201180068009 A CN 201180068009A CN 103380212 B CN103380212 B CN 103380212B
Authority
CN
China
Prior art keywords
cells
cell
pluripotent
inhibitor
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180068009.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103380212A (zh
Inventor
巴莱姆·瓦拉莫河
拉姆泽伊·阿布加罗尔
彼得·弗林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Priority to CN202111314859.6A priority Critical patent/CN114164167B/zh
Priority to CN201710089787.7A priority patent/CN106893692B/zh
Publication of CN103380212A publication Critical patent/CN103380212A/zh
Application granted granted Critical
Publication of CN103380212B publication Critical patent/CN103380212B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201180068009.0A 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台 Active CN103380212B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202111314859.6A CN114164167B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台
CN201710089787.7A CN106893692B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201061426369P 2010-12-22 2010-12-22
US61/426,369 2010-12-22
US201161496991P 2011-06-14 2011-06-14
US61/496,991 2011-06-14
PCT/US2011/065900 WO2012087965A2 (en) 2010-12-22 2011-12-19 Cell culture platform for single cell sorting and enhanced reprogramming of ipscs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202111314859.6A Division CN114164167B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台
CN201710089787.7A Division CN106893692B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台

Publications (2)

Publication Number Publication Date
CN103380212A CN103380212A (zh) 2013-10-30
CN103380212B true CN103380212B (zh) 2017-04-05

Family

ID=46314809

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201180068009.0A Active CN103380212B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台
CN201710089787.7A Active CN106893692B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台
CN202111314859.6A Active CN114164167B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710089787.7A Active CN106893692B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台
CN202111314859.6A Active CN114164167B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台

Country Status (8)

Country Link
US (3) US9732319B2 (enExample)
EP (1) EP2655601A4 (enExample)
JP (6) JP6182456B2 (enExample)
KR (6) KR102482184B1 (enExample)
CN (3) CN103380212B (enExample)
AU (1) AU2011349446C1 (enExample)
CA (1) CA2822638C (enExample)
WO (1) WO2012087965A2 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP3061808B1 (en) 2009-02-03 2020-08-12 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
KR102482184B1 (ko) 2010-12-22 2022-12-28 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
US10428309B2 (en) * 2011-12-01 2019-10-01 New York Stem Cell Foundation, Inc. Systems and methods for producing stem cells and differentiated cells
EP2785829B1 (en) 2011-12-01 2019-10-16 New York Stem Cell Foundation, Inc. Automated system for producing induced pluripotent stem cells or differentiated cells
WO2014106947A1 (en) * 2013-01-04 2014-07-10 Kyoto University Reprogrammed stem cell
WO2014115799A1 (ja) * 2013-01-23 2014-07-31 東京エレクトロン株式会社 多能性幹細胞の継代培養方法
EP2948541B1 (en) * 2013-01-28 2019-09-18 Rutgers, The State University of New Jersey Growth matrices for stem cell propagation in vitro and in tissue regeneration
AU2014218290B2 (en) * 2013-02-18 2020-03-12 The Hospital For Sick Children Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
US20160122720A1 (en) * 2013-06-11 2016-05-05 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2014201133A1 (en) * 2013-06-11 2014-12-18 President And Fellows Of Harvard College Compositions and methods for improving induced neuron generation
CN103333920A (zh) * 2013-06-18 2013-10-02 西北农林科技大学 一种建立猪iPS细胞系的培养基及其培养方法
CN104278008B (zh) * 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 一种通过小分子化合物处理来制备多潜能干细胞的方法、试剂盒和用途
CA2914520A1 (en) 2013-07-23 2015-01-29 F. Hoffmann-La Roche Ag Small molecule based conversion of somatic cells into neural crest cells
KR101655383B1 (ko) * 2013-07-27 2016-09-08 고려대학교 산학협력단 소분자 화합물을 포함하는 만능성 줄기세포의 염색체 안정성 유지용 조성물
US10067145B2 (en) * 2013-10-30 2018-09-04 Toagosei Co., Ltd. Method for removing genomically unstable IPS cells and synthetic peptide used therefor
KR101697110B1 (ko) * 2013-11-01 2017-01-18 건국대학교 글로컬산학협력단 세포융합을 통한 줄기세포의 역분화능 측정 방법
CN103667349B (zh) * 2013-11-15 2017-02-15 安徽农业大学 一种高效获取猪诱导性多能干细胞的方法
KR20240091064A (ko) * 2014-03-04 2024-06-21 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
US10597633B2 (en) 2014-05-16 2020-03-24 Koninklijke Nederlandse Akademie Van Wetenschappen Culture method for organoids
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
SG11201701398SA (en) * 2014-08-22 2017-03-30 Cambridge Entpr Ltd Resetting pluripotent stem cells
CN105441384B (zh) * 2014-09-26 2021-01-05 北京大学 一种制备动物和人类原始多潜能干细胞的方法，试剂盒及用途
WO2016057649A1 (en) * 2014-10-07 2016-04-14 NuTech Medical, Inc. Mesenchymal stem cell diagnostic testing
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421092D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
CN113234661A (zh) * 2014-12-18 2021-08-10 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
SG10202101358XA (en) 2015-01-26 2021-03-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
US10738280B2 (en) 2015-03-18 2020-08-11 Ono Pharmaceutical Co., Ltd. Method for producing naïve pluripotent stem cells
CN104707173B (zh) * 2015-04-01 2017-03-29 中国人民解放军总医院 一种三维细胞培养平台、其制备方法及其使用方法
US10712356B2 (en) 2015-04-21 2020-07-14 General Automation Lab Technologies Inc. Apparatus and method for picking biological sample
CN114015569A (zh) 2015-04-21 2022-02-08 通用自动化实验技术公司 用于高通量微生物学应用的高分辨率系统、试剂盒、设备和方法
CN105624104B (zh) * 2015-06-01 2018-10-12 中国医学科学院血液病医院（血液学研究所） 一种提高人间充质干细胞功能的细胞处理方法
WO2017027280A1 (en) 2015-08-07 2017-02-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Chemical reprogramming to generate neuronal cells
US11286454B2 (en) * 2015-08-31 2022-03-29 I Peace, Inc. Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells
EP4001402A1 (en) 2015-09-08 2022-05-25 FUJIFILM Cellular Dynamics, Inc. Macs-based purification of stem cell-derived retinal pigment epithelium
AU2016321170B2 (en) 2015-09-08 2022-09-01 Fujifilm Cellular Dynamics Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
US12385008B2 (en) * 2015-09-08 2025-08-12 Sumitomo Pharma Co., Ltd. Method for producing retinal tissue
CA2997528C (en) 2015-09-08 2024-02-13 Sumitomo Dainippon Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
US11441126B2 (en) * 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
ES2862676T3 (es) 2015-10-20 2021-10-07 Fujifilm Cellular Dynamics Inc Producción de células precursoras hematopoyéticas multilinaje mediante programación genética
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
ES2953925T3 (es) * 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
US20190282624A1 (en) * 2015-11-30 2019-09-19 Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. Improved methods for reprograming non-pluripotent cells into pluripotent stem cells
KR20180114032A (ko) * 2016-01-08 2018-10-17 국립연구개발법인 고쿠리츠간켄큐센터 저분자 화합물에 의한 성숙 간세포로부터의 간 줄기/전구세포의 제작 방법
WO2017134628A1 (en) * 2016-02-03 2017-08-10 The Regents Of The University Of California Methods and compositions for culturing stem cells
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
CN105950548A (zh) * 2016-05-26 2016-09-21 南京医科大学附属南京儿童医院 一种从间充质干细胞高效获取可跳动有功能心肌细胞的方法
EP3487987A4 (en) * 2016-07-19 2020-02-19 Accellta Ltd. CULTURAL MEDIA FOR THE CULTURE OF PLURIPOTENTAL STEM CELLS IN A SUSPENSION
JPWO2018047941A1 (ja) * 2016-09-08 2019-07-11 協和発酵バイオ株式会社 幹細胞培養用培地、幹細胞の培養方法、幹細胞の増殖促進剤、並びに細胞組成物およびその製造方法
WO2018079714A1 (ja) * 2016-10-28 2018-05-03 国立研究開発法人国立がん研究センター ヒト肝前駆細胞の調製方法
CN106754729B (zh) * 2016-12-31 2020-03-17 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法
JP7007686B2 (ja) 2017-03-08 2022-01-25 大日本住友製薬株式会社 網膜色素上皮細胞の製造方法
AU2018254442B2 (en) 2017-04-18 2024-03-28 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
WO2018203499A1 (ja) * 2017-05-02 2018-11-08 剛士 田邊 医薬品組成物及び化粧品組成物
EP3406712A1 (en) 2017-05-26 2018-11-28 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Method for expanding stemness and differentiation potential of pluripotent cells
AU2018348142B2 (en) 2017-10-11 2025-04-17 Fate Therapeutics, Inc. Cellular reprogramming using temporal and transient plasmid vector expression system
JP6680742B2 (ja) 2017-10-31 2020-04-15 大研医器株式会社 磁性粒子収集方法及び試験セット
US20190167724A1 (en) * 2017-12-04 2019-06-06 Caire Medical-Biotechnology International Co. Neuroprotective composition, preparation process thereof and medical uses thereof
CN108265025A (zh) * 2017-12-28 2018-07-10 安徽中盛溯源生物科技有限公司 一种人类诱导多能干细胞的重编程培养基
WO2019151386A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 細胞の製造方法
JP7097050B2 (ja) * 2018-03-19 2022-07-07 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
EP3810758B1 (en) * 2018-06-20 2023-07-19 BioLamina AB Methods and compositions for producing retinal pigment epithelium cells
WO2020027094A1 (ja) * 2018-07-31 2020-02-06 サイアス株式会社 ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法
WO2020050673A1 (ko) 2018-09-07 2020-03-12 주식회사 차바이오텍 다능성 줄기세포 유래 중간엽 줄기세포 직접 분화용 배지, 그를 이용하여 중간엽 줄기세포를 제조하는 방법, 및 그에 의해 제조된 중간엽 줄기세포
AU2019360857A1 (en) * 2018-10-15 2021-06-03 Evia Life Sciences Inc. Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
EP3933033A4 (en) * 2019-02-26 2022-11-23 Tohoku University METHOD FOR PRODUCING AN AGGREGATE OF OSTEOBLASTS USING HUMAN IPS CELLS
CN109938987B (zh) * 2019-03-15 2024-06-04 首都医科大学宣武医院 放置于口腔内部的抽动障碍治疗器
US20220099540A1 (en) * 2019-03-20 2022-03-31 Ion Diagnostics Llc Methods and systems for assessing bioelectric patterns
JP2022535192A (ja) 2019-05-14 2022-08-05 アレフ ファームス リミテッド 多能性細胞凝集体およびそれらの使用
CN112301052A (zh) * 2019-08-01 2021-02-02 浙江霍德生物工程有限公司 一种通过体细胞重编程制备诱导多功能干细胞的方法
BR112022005225A2 (pt) * 2019-09-19 2022-08-16 Univ Northwestern Meio de cultura econômico e protocolo para células-tronco pluripotentes induzidas humanas
KR20230026433A (ko) * 2020-06-22 2023-02-24 라이프 테크놀로지스 코포레이션 전분화능 세포 현탁액을 배양하기 위한 방법 및 조성물
CN116348592A (zh) * 2020-10-02 2023-06-27 菲特治疗公司 诱导性多能干细胞的改善的重编程、维持和保存
GB202115676D0 (en) * 2021-11-01 2021-12-15 Icahn School Med Mount Sinai Methods and compositions for bat ipsc preparation and use
EP4170018A1 (en) * 2021-10-20 2023-04-26 Roslin Technologies Limited Ipsc induction and progeny derivation
WO2023067090A1 (en) * 2021-10-20 2023-04-27 Roslin Technologies Limited Ipsc induction and progeny derivation
CN114591894B (zh) * 2022-02-28 2024-01-09 中国人民解放军总医院 一种皮肤多能前体干细胞的制备方法及其应用
EP4495229A4 (en) * 2022-03-14 2025-12-24 Space F Corp MEDIUM COMPOSITION FOR THE CULTURE OF PORCINE PLURIPOTENT STEM CELLS
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025152036A1 (en) * 2024-01-16 2025-07-24 Chiou Guang Yuh System and method for increasing the transduction capability and reprogramming efficiency in targeting cells and tissues
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563449A (zh) * 2006-09-22 2009-10-21 理化学研究所 干细胞培养基及干细胞培养方法
CN102597221A (zh) * 2009-11-04 2012-07-18 细胞动力国际有限公司 使用化学品的游离重编程

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
KR940702451A (ko) 1991-09-06 1994-08-20 고야 다다시 4-아미로(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
WO1995003402A1 (en) 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
IL128456A0 (en) 1996-08-12 2000-01-31 Yoshitomi Pharmaceutical Compositions containing a Rho kinase inhibitor
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6030943A (en) 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
JP3626206B2 (ja) 1997-06-13 2005-03-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ６及びその使用
CA2290506C (en) 1997-07-01 2005-12-27 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
CA2336220A1 (en) 1998-07-24 2000-02-03 The Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the tgf-.beta. family of growth factors
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
BR9916785A (pt) 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
AU5250400A (en) 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
AU6865100A (en) 1999-09-02 2001-04-10 Mitsubishi Pharma Corporation Osteogenesis promoting agents
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
NZ524120A (en) 2000-07-19 2005-08-26 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2008108741A1 (en) 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
JP4320705B2 (ja) 2001-03-23 2009-08-26 バイエル コーポレイション Ｒｈｏキナーゼ阻害剤
AU2002250394A1 (en) 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
ATE452972T1 (de) 2001-05-01 2010-01-15 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
AU2002330465B2 (en) 2001-09-21 2006-07-27 Kyoto University Screening method for a reprogramming agent, reprogramming agent screened by the method, method for using the reprogramming agent, method for differentiating an undifferentiated fusion cell, and production method of cells, tissues and organs.
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
JP4423043B2 (ja) 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
WO2003062225A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
US20030204862A1 (en) 2002-03-05 2003-10-30 Ralf Kuehn Inbred embryonic stem-cell derived mice
PL401638A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
US20050182040A1 (en) 2002-04-03 2005-08-18 Naonori Imazaki Benzamide derivatives
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
JP4681451B2 (ja) 2002-10-28 2011-05-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤としてのヘテロアリールオキシ置換フェニルアミノピリミジン類
AU2003274576A1 (en) 2002-11-15 2004-06-15 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
SI1572984T1 (sl) * 2002-12-16 2016-07-29 Technion Research & Development Foundation Ltd. Kulturni sistem brez hranilnih celic, brez kseno-komponent, za humane embrionalne matične celice
AU2004212490B2 (en) 2003-02-10 2008-05-15 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
WO2005084158A2 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
US7727762B2 (en) 2003-10-03 2010-06-01 Keiichi Fukuda Method of inducing the differentiation of stem cells into myocardial cells
KR101163800B1 (ko) 2003-10-15 2012-07-09 산텐 세이야꾸 가부시키가이샤 신규 인다졸 유도체
NZ547105A (en) 2003-10-16 2009-02-28 Univ Edinburgh Control of ES cell self-renewal and lineage specification, and medium therefor
AU2004291559B2 (en) 2003-11-19 2008-10-16 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
ATE495155T1 (de) 2003-11-19 2011-01-15 Array Biopharma Inc Heterocyclische inhibitoren von mek
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
JP2007519754A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
CN1997660A (zh) 2004-04-21 2007-07-11 芝加哥大学 肌球蛋白轻链激酶抑制剂及其使用
US8187878B2 (en) 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
WO2006026473A2 (en) 2004-08-25 2006-03-09 University Of Georgia Research Foundation, Inc. METHODS AND COMPOSITIONS UTILIZING MYC AND GSK3ß TO MANIPULATE THE PLURIPOTENCY OF EMBRYONIC STEM CELLS
US20060182724A1 (en) 2005-02-15 2006-08-17 Riordan Neil H Method for expansion of stem cells
TW201238952A (en) 2005-05-18 2012-10-01 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof
CA2617611A1 (en) 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
WO2007030693A2 (en) 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP4223769A3 (en) 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
JPWO2007088651A1 (ja) 2006-02-01 2009-06-25 国立大学法人 東京大学 ＴＧＦ−βシグナル阻害剤と抗腫瘍剤の組み合せ使用
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
GB2436737B (en) 2006-03-30 2008-07-09 Univ Edinburgh Culture medium containing kinase inhibitors,and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US20070259423A1 (en) 2006-05-02 2007-11-08 Jon Odorico Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
US20070298496A1 (en) * 2006-06-23 2007-12-27 Hung-Chih Kuo Method of deriving pluripotent stem cells from a single blastomere
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AR061974A1 (es) 2006-07-14 2008-08-10 Novartis Ag Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
WO2008089351A1 (en) 2007-01-17 2008-07-24 Wisconsin Alumni Research Foundation Improved culture of stem cells
WO2008088882A2 (en) 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
AU2008211103B2 (en) 2007-01-30 2014-05-08 University Of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (MMC)
US8158415B2 (en) 2007-02-27 2012-04-17 Procell Therapeutics Inc. Combined use of cell permeable Nanog and Oct4 for increasing self-renewal and suppressing differentiation of stem cells
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
CN101688178B (zh) 2007-04-18 2013-12-04 哈达锡特医学研究服务及发展有限公司 干细胞衍生的视网膜色素上皮细胞
US7878210B2 (en) 2007-06-04 2011-02-01 Philip Morris Usa Inc. Cellulose acetate fiber modification
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US8815585B2 (en) 2007-06-29 2014-08-26 Cellular Dynamics International, Inc. Automated method and apparatus for embryonic stem cell culture
US20120282229A1 (en) 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
EP3078738B1 (en) 2007-08-31 2020-05-20 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
EP2227540A4 (en) 2007-11-29 2011-11-02 Children S Hospital Of Orange County DIFFERENTIATION OF HUMAN CELLS
WO2009067757A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving oct4 protein
AU2008329562A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Sox2 protein
US9534205B2 (en) 2008-03-17 2017-01-03 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
WO2009115295A1 (en) 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
WO2010013845A1 (en) 2008-07-30 2010-02-04 Kyoto University Method of efficiently establishing induced pluripotent stem cells
EP3330371A1 (en) * 2008-08-12 2018-06-06 Cellular Dynamics International, Inc. Methods for the production of ips cells
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
IL289685B2 (en) * 2008-11-04 2025-09-01 Viacyte Inc Stem cell pool suspension preparations and methods for their differentiation
EP4585589A3 (en) 2008-12-03 2025-11-19 The Scripps Research Institute Stem cell cultures
JP6093110B2 (ja) * 2008-12-17 2017-03-08 ザ スクリプス リサーチ インスティテュート 幹細胞の作製と維持
CA2688804A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic vector for human induced pluripotent stem cell production
US20120122212A1 (en) 2009-03-06 2012-05-17 Marica Grskovic Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
KR20110134939A (ko) 2009-04-03 2011-12-15 더 맥클린 하스피털 코퍼레이션 유도된 다능성 줄기 세포
CN102395672A (zh) 2009-04-13 2012-03-28 加利福尼亚大学董事会 用于干细胞培养的方法和组合物
RU2011153283A (ru) * 2009-05-27 2013-07-10 Те Солк Инститьют Фор Байолоджикал Стадиз Получение генетически скорректированных, здоровых индуцированных плюрипотентных стволовых клеток
US8524498B2 (en) 2009-05-29 2013-09-03 The General Hospital Corporation Methods and compositions for homologous recombination in human cells
US9005975B2 (en) 2009-05-29 2015-04-14 Kyoto University Method for selecting clone of induced pluripotent stem cells
SG10201608797WA (en) 2009-08-07 2016-12-29 Univ Kyoto Method of efficiently establishing induced pluripotent stem cells
BR112012008848A2 (pt) 2009-10-16 2019-09-24 Scripps Research Inst composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas
MX390753B (es) * 2009-10-31 2025-03-21 Genesis Tech Limited Metodos para reprogramar celulas y usos de los mismos.
WO2011058558A2 (en) 2009-11-12 2011-05-19 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011090221A1 (en) 2010-01-22 2011-07-28 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
CA2789774C (en) 2010-02-17 2024-01-23 Biotime Inc. Methods for telomere length and genomic dna quality control analysis in pluripotent stem cells
ES2533581T3 (es) 2010-03-05 2015-04-13 Texas Heart Institute ETS2 y Mesp1 generadores de progenitores cardíacos a partir de fibroblastos
ES2893699T3 (es) 2010-03-31 2022-02-09 Scripps Research Inst Reprogramación de células
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
CN103003416B (zh) * 2010-06-15 2016-11-16 细胞动力学国际有限公司 从小体积的外周血产生诱导性多潜能干细胞
JPWO2011158852A1 (ja) 2010-06-15 2013-08-19 国立大学法人 東京大学 誘導型多能性幹細胞の製造方法
EP2601289B1 (en) * 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
KR102482184B1 (ko) 2010-12-22 2022-12-28 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
US9458131B2 (en) 2011-11-08 2016-10-04 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
HK1203081A1 (en) 2011-12-08 2015-10-16 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013159103A1 (en) 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
EP2853590B1 (en) 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation
KR20240091064A (ko) 2014-03-04 2024-06-21 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
ES2953925T3 (es) 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563449A (zh) * 2006-09-22 2009-10-21 理化学研究所 干细胞培养基及干细胞培养方法
CN102597221A (zh) * 2009-11-04 2012-07-18 细胞动力国际有限公司 使用化学品的游离重编程

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Reprogramming of human primary somatic cells by OCT4 and chemical compounds;Saiyong Zhu et al,;《Cell Stem Cell 》;20101203;1第651页左栏倒数第12行至第653页左栏第2段以及对比文件1所引用的文献：Li et al.,2009和Lin et al.,2009 *
A chemical platform for improved induction of human iPSCs;Tongxiang Lin et al;《Nat Methods.》;20091130;805-808 *
A ROCK inhibitor permits survival of dissociated human embryonic stem cells;Kiichi Watanabe et al;《NATURE BIOTECHNOLOGY》;20070630;681-686 *
Generation of Human-Induced Pluripotent Stem Cells in the Absence of Exogenous Sox2;WENLIN LI ET AL;《STEM CELLS》;20091231;2992-3000 *
The ROCK inhibitor Y-27632 improves recovery of human embryonic stem cells after fluorescence-activated cell sorting with multiple cell surface markers;Nil Emre et al;《PLoS ONE》;20100831;摘要、第2页右栏第2、3段、结果部分 *

Also Published As

Publication number Publication date
CN103380212A (zh) 2013-10-30
WO2012087965A2 (en) 2012-06-28
JP2023138509A (ja) 2023-10-02
JP2025039573A (ja) 2025-03-21
JP7513412B2 (ja) 2024-07-09
KR20140063501A (ko) 2014-05-27
KR20190049918A (ko) 2019-05-09
EP2655601A2 (en) 2013-10-30
KR20230006038A (ko) 2023-01-10
US9732319B2 (en) 2017-08-15
CN106893692A (zh) 2017-06-27
KR102703637B1 (ko) 2024-09-05
KR20170064555A (ko) 2017-06-09
US20210079359A1 (en) 2021-03-18
US20140220681A1 (en) 2014-08-07
AU2011349446A1 (en) 2013-04-11
JP6682474B2 (ja) 2020-04-15
JP2014501108A (ja) 2014-01-20
KR102482184B1 (ko) 2022-12-28
JP7350127B2 (ja) 2023-09-25
AU2011349446B2 (en) 2015-09-03
CN106893692B (zh) 2021-11-26
US12415989B2 (en) 2025-09-16
US10844356B2 (en) 2020-11-24
JP6182456B2 (ja) 2017-08-23
US20170362569A1 (en) 2017-12-21
KR102160721B1 (ko) 2020-09-29
JP2017158585A (ja) 2017-09-14
EP2655601A4 (en) 2014-09-10
JP2020108399A (ja) 2020-07-16
KR20210097834A (ko) 2021-08-09
CA2822638C (en) 2021-02-16
AU2011349446C1 (en) 2016-01-21
JP2022097516A (ja) 2022-06-30
CA2822638A1 (en) 2012-06-28
KR101975688B1 (ko) 2019-05-07
JP7606569B2 (ja) 2024-12-25
WO2012087965A3 (en) 2012-10-04
KR20200113286A (ko) 2020-10-06
CN114164167B (zh) 2025-02-21
CN114164167A (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
JP7350127B2 (ja) 単細胞選別のための細胞培養プラットホームおよびｉＰＳＣの再プログラミングの増強
US12385012B2 (en) Methods and compositions for inducing hematopoietic cell differentiation
HK40068498A (zh) 用於单细胞分选与增强ipsc重新编程的细胞培养平台
HK1239743A1 (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK1239743B (zh) 用於单细胞分选与增强ipsc重新编程的细胞培养平台
HK1191049A (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK1191049B (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1191049

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1191049

Country of ref document: HK